vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $14.6M, roughly 1.3× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -0.8%, a 65.1% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs -25.7%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-15.8M). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
CTMX vs IDR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $14.6M |
| Net Profit | $-154.0K | $9.4M |
| Gross Margin | — | 68.5% |
| Operating Margin | -6.9% | 62.4% |
| Net Margin | -0.8% | 64.3% |
| Revenue YoY | -25.7% | 92.0% |
| Net Profit YoY | 97.6% | 220.6% |
| EPS (diluted) | — | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $11.1M | ||
| Q2 25 | $18.7M | $9.5M | ||
| Q1 25 | $50.9M | $7.3M | ||
| Q4 24 | $38.1M | $7.6M | ||
| Q3 24 | $33.4M | $6.2M | ||
| Q2 24 | $25.1M | $6.1M | ||
| Q1 24 | $41.5M | $5.9M |
| Q4 25 | — | $9.4M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $-154.0K | $2.8M | ||
| Q1 25 | $23.5M | $1.6M | ||
| Q4 24 | $18.9M | $2.9M | ||
| Q3 24 | $5.7M | $1.6M | ||
| Q2 24 | $-6.5M | $2.2M | ||
| Q1 24 | $13.8M | $2.2M |
| Q4 25 | — | 68.5% | ||
| Q3 25 | — | 63.6% | ||
| Q2 25 | — | 57.8% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 53.3% | ||
| Q3 24 | — | 48.7% | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | 48.1% |
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | -6.9% | 26.6% | ||
| Q1 25 | 44.4% | 19.3% | ||
| Q4 24 | 46.4% | 36.2% | ||
| Q3 24 | 12.3% | 23.4% | ||
| Q2 24 | -33.7% | 34.2% | ||
| Q1 24 | 28.1% | 36.3% |
| Q4 25 | — | 64.3% | ||
| Q3 25 | — | 26.8% | ||
| Q2 25 | -0.8% | 29.2% | ||
| Q1 25 | 46.2% | 22.1% | ||
| Q4 24 | 49.6% | 38.5% | ||
| Q3 24 | 17.2% | 25.8% | ||
| Q2 24 | -26.0% | 35.2% | ||
| Q1 24 | 33.3% | 36.8% |
| Q4 25 | — | $0.62 | ||
| Q3 25 | — | $0.20 | ||
| Q2 25 | — | $0.20 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $0.21 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $2.3M |
| Stockholders' EquityBook value | $119.9M | $108.2M |
| Total Assets | $175.1M | $116.2M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | $6.3M | ||
| Q1 24 | $36.2M | $5.3M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | $3.3M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | — | $108.2M | ||
| Q3 25 | — | $74.3M | ||
| Q2 25 | $119.9M | $49.3M | ||
| Q1 25 | $25.0M | $39.8M | ||
| Q4 24 | $-456.0K | $37.7M | ||
| Q3 24 | $-23.5M | $33.1M | ||
| Q2 24 | $-31.2M | $25.4M | ||
| Q1 24 | $-31.7M | $21.6M |
| Q4 25 | — | $116.2M | ||
| Q3 25 | — | $83.1M | ||
| Q2 25 | $175.1M | $57.7M | ||
| Q1 25 | $98.5M | $48.1M | ||
| Q4 24 | $120.5M | $44.0M | ||
| Q3 24 | $139.0M | $40.8M | ||
| Q2 24 | $159.2M | $32.2M | ||
| Q1 24 | $184.7M | $28.7M |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $10.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $8.2M |
| FCF MarginFCF / Revenue | -84.6% | 56.0% |
| Capex IntensityCapex / Revenue | 0.1% | 17.7% |
| Cash ConversionOCF / Net Profit | — | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $12.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-15.8M | $3.5M | ||
| Q1 25 | $-21.0M | $2.4M | ||
| Q4 24 | $-19.9M | $3.2M | ||
| Q3 24 | $-20.7M | $2.5M | ||
| Q2 24 | $-19.5M | $2.6M | ||
| Q1 24 | $-26.0M | $2.6M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | — | $709.8K | ||
| Q2 25 | $-15.8M | $2.5M | ||
| Q1 25 | $-21.2M | $1.0M | ||
| Q4 24 | $-20.0M | $2.1M | ||
| Q3 24 | $-20.7M | $1.9M | ||
| Q2 24 | $-19.6M | $2.4M | ||
| Q1 24 | $-26.2M | $2.3M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | -84.6% | 26.5% | ||
| Q1 25 | -41.6% | 13.8% | ||
| Q4 24 | -52.5% | 28.0% | ||
| Q3 24 | -62.1% | 30.4% | ||
| Q2 24 | -78.2% | 38.7% | ||
| Q1 24 | -63.1% | 38.3% |
| Q4 25 | — | 17.7% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | 0.1% | 10.8% | ||
| Q1 25 | 0.2% | 19.4% | ||
| Q4 24 | 0.2% | 13.6% | ||
| Q3 24 | 0.1% | 9.8% | ||
| Q2 24 | 0.4% | 4.3% | ||
| Q1 24 | 0.3% | 5.5% |
| Q4 25 | — | 1.15× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.28× | ||
| Q1 25 | -0.89× | 1.50× | ||
| Q4 24 | -1.05× | 1.08× | ||
| Q3 24 | -3.61× | 1.56× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | -1.89× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
IDR
Segment breakdown not available.
